Riskpilot← Back to searchSign inGet full accessAsgard Therapeutics AB
ABActiveOrg 5591840136LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20189 employees
Revenue 2024
SEK 0
EBITDA margin
—
-139% vs 2023
Equity ratio
92.5%
Financial strength
Net profit 2024
SEK -65,5M
-132% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -67,8M | -139% |
| Net profit | SEK -65,5M | -132% |
| Total assets | SEK 104,9M | +819% |
| Equity | SEK 97,1M | +1903% |
| Employees | 9 | — |
Legal name
Asgard Therapeutics AB
Org number
5591840136
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
6 december 2018
Share capital
SEK 265 000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, bedriva forskning och utveckling, tillverkning och handel med cell-, medicinska-diagnostiska-, farmaceutiska- och kemiska-tekniska produkter, förvärv, upplåta och överlåta immateriella rättigheter för sådana produkter samt att bedriva därmed förenlig verksamhet.
Address
Lund
Email
cristiana.pires@asgardthx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 433 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 186 | −1 476 | −27 191 | −28 365 | −67 840 |
| Depreciation & amort. | −0 | −0 | −1 472 | −3 | −399 |
| EBIT | 186 | −1 476 | −28 663 | −28 368 | −68 239 |
| Net financials | — | 581 | −374 | 198 | 2 789 |
| Profit before tax | 151 | −860 | −29 037 | −28 170 | −65 450 |
| Tax | −22 | −0 | −0 | −0 | −0 |
| Net profit | 129 | −860 | −29 037 | −28 170 | −65 450 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 436 | 20 619 | 35 680 | 11 421 | 104 918 |
| Equity | 621 | 18 554 | 33 017 | 4 847 | 97 085 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 781 | 2 064 | 2 663 | 6 574 | 7 833 |
| Total debt | 781 | 2 064 | 2 663 | 6 574 | 7 833 |
EBITDA margin
-6784000000.0%
This company
15.8%
Market median
-42936708961% vs market
20202024
Equity ratio
92.5%
This company
38.2%
Market median
+142% vs market
20202024
Return on equity
-67.4%
This company
18.4%
Market median
-466% vs market
20202024
Net profit margin
-6545000000.0%
This company
8.1%
Market median
-80802469236% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CF Chief Executive Officer | Chief Executive Officer | 2020 |
KE Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
PÅ Chief Auditor | Chief Auditor | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2020 | |
| Board of Directors | 2025 | |
| Chairman | 2022 | |
| Board of Directors | 2026 | |
| Former (6) | ||
| Chairman | 2020 – 2021 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2024 – 2026 | |
| Chairman | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Asgard Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cristiana Ferreira Pires | Chief Executive Officer | 0 companies |
| Per Åke Joakim Stomberg | Chief Auditor | 0 companies |
| Kristina Elisabeth Winther | Chief Auditor | 0 companies |
| Karin Marie Christine Widstrand | Chairman | 0 companies |
| Jonas Jendi | Board of Directors | 0 companies |
| Alexey Zeifman | Board of Directors | 0 companies |
| Carlos Filipe Ribeiro Lemos Pereira | Board of Directors | 0 companies |
| Joao Carlos Ribas de Almeida | Board of Directors | 0 companies |
| Nils Gunnar Gårdemyr | Board of Directors | 0 companies |
| Philipp Müller | Board of Directors | 0 companies |
| Aleksei Zeifman | Board of Directors | 0 companies |
| Søren Møller | Board of Directors | 0 companies |
| Fiona Caroline MacLaughlin | Board of Directors | 0 companies |
| Lars Olof Hedbys | Chairman | 0 companies |
| Cristina Ileana Csimma | Board of Directors | 0 companies |
| Martin Bonde | Chairman | 0 companies |
| Nadiya Ishnazarova | Board of Directors | 0 companies |